Jazz Pharmaceuticals files patent infringement claims against Roxane Laboratories over generic version of XYREM®
Clients Jazz Pharmaceuticals, Inc.
Jones Day represents plaintiff Jazz Pharmaceuticals, Inc. in a Hatch-Waxman ANDA patent litigation involving a proposed generic version of sodium oxybate, which is sold under the brand name XYREM®, and is prescribed in the treatment of narcolepsy.
Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc., Civil Action No. 2-10-cv-06108 (D.N.J.) (Judge Wigenton)